Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $27.00 at The Goldman Sachs Group

Day One Biopharmaceuticals (NASDAQ:DAWN) had its target price cut by The Goldman Sachs Group from $39.00 to $27.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also issued reports on DAWN. JPMorgan Chase & Co. dropped their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. HC Wainwright dropped their price target on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Bank of America lowered their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Wedbush restated an “outperform” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $32.29.

Day One Biopharmaceuticals Price Performance

DAWN opened at $8.28 on Tuesday. The firm has a market capitalization of $839.22 million, a price-to-earnings ratio of -8.04 and a beta of -1.38. The company’s 50 day simple moving average is $10.84 and its two-hundred day simple moving average is $12.72. Day One Biopharmaceuticals has a 1-year low of $7.88 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analysts’ expectations of $27.11 million. On average, equities analysts anticipate that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at $1,531,059.40. This represents a 8.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. This trade represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,064 shares of company stock valued at $251,925. 8.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DAWN. Quest Partners LLC raised its position in Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Day One Biopharmaceuticals during the third quarter worth approximately $324,000. Charles Schwab Investment Management Inc. raised its holdings in Day One Biopharmaceuticals by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock valued at $7,069,000 after acquiring an additional 64,700 shares in the last quarter. Algert Global LLC lifted its stake in Day One Biopharmaceuticals by 248.8% in the third quarter. Algert Global LLC now owns 71,487 shares of the company’s stock worth $996,000 after acquiring an additional 50,990 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Day One Biopharmaceuticals during the 3rd quarter worth approximately $174,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.